Does utricaria vasulitis blanch ?
Reading File
Finding Sources
Searching the Web
urticarial vasculitis blanching diascopy clinical features
Urticaria Vasculitis - Does it Blanch?
No - urticarial vasculitis typically does NOT blanch (or blanches only partially) on pressure (diascopy). This is one of its key distinguishing features from ordinary urticaria.
Why it doesn't blanch
In normal urticaria, the redness is caused by vascular dilation and plasma leakage - pressing on the skin (diascopy) pushes blood out of vessels, so the lesion turns white. In urticarial vasculitis, there is actual vessel wall inflammation and destruction, leading to extravasation of red blood cells into the surrounding tissue (purpuric component). Red blood cells outside vessels cannot be pushed away by pressure, so the lesion does not blanch.
Key clinical distinction from ordinary urticaria
| Feature | Ordinary Urticaria | Urticarial Vasculitis |
|---|---|---|
| Blanching on pressure | Yes - fully blanches | No (or incomplete blanching) |
| Duration of individual lesion | < 24 hours | > 24-48 hours |
| Sensation | Itchy | Often painful or burning |
| Purpuric component | Absent | Often present |
| Resolution | Clean | Leaves post-inflammatory hyperpigmentation |
| Biopsy | Normal | Leukocytoclastic vasculitis |
As Goldman-Cecil Medicine states directly: "the lesions of urticarial vasculitis persist for more than 48 hours, often have a purpuric component (i.e., they do not blanch), and resolve with postinflammatory hyperpigmentation."
A 2026 clinical profile study from China confirmed that 76.1% of urticarial vasculitis wheals showed partial or complete non-blanching, reinforcing this as a reliable bedside sign.
Bottom line
Non-blanching (or partial non-blanching) on diascopy = important red flag that should prompt biopsy to rule out urticarial vasculitis, especially if lesions also last > 24 hours or leave bruising behind.
Treatment of both
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Here is a structured breakdown of treatment for both conditions:
Treatment of Ordinary Urticaria
Step 1 - First-line (Non-sedating 2nd generation H1 antihistamines)
These are the backbone of urticaria management:
- Cetirizine, Loratadine, Fexofenadine, Bilastine, Rupatadine
- Can be up-dosed up to 4x the standard dose if response is inadequate
Step 2 - Add-ons / Second-line
| Drug | Class | Dose | Note |
|---|---|---|---|
| Short-acting sedating antihistamine (e.g. chlorphenamine) | H1 blocker | At night | Combined with 2nd-gen for max blockade |
| Ranitidine / Famotidine | H2 blocker | Standard | Added to H1 antihistamine |
| Montelukast | Leukotriene antagonist | 10 mg/day | Especially aspirin-sensitive urticaria |
| Dapsone | Aminosalicylate | 50-100 mg/day | Refractory CSU, neutrophilic pattern |
| Colchicine | Neutrophil inhibitor | 0.5-1.8 mg/day | Neutrophilic infiltrate on biopsy |
| Doxepin | Tricyclic (H1+H2 blocker) | At night | Potent; monitor serum levels |
Step 3 - Rescue / Refractory
- Prednisone/Prednisolone 0.5 mg/kg/day - short courses only (days), for severe exacerbations
- Omalizumab (anti-IgE) - for refractory chronic spontaneous urticaria (CSU); highly effective
- Epinephrine 300-500 mcg IM/SC - for angioedema of throat / anaphylaxis
Non-drug measures
- Avoid triggers (food additives, NSAIDs, physical stimuli)
- Low pseudoallergen diet in refractory cases
Treatment of Urticarial Vasculitis
Treatment is directed at symptomatology and disease severity, and differs significantly depending on whether it is normocomplementemic (milder) or hypocomplementemic (more severe, systemic).
Mild disease
| Drug | Notes |
|---|---|
| Antihistamines | First step but often ineffective |
| Indomethacin (NSAID) | Particularly effective - first drug to try |
| Dapsone | Effective; anti-neutrophilic mechanism |
| Colchicine | Useful, especially with neutrophilic infiltrate |
| Antimalarials (hydroxychloroquine) | Useful for mild-moderate disease |
| Pentoxifylline | May be added to dapsone for better efficacy |
Moderate-Severe / Hypocomplementemic UV
| Drug | Notes |
|---|---|
| Prednisone | Standard immunosuppression |
| Azathioprine | Steroid-sparing agent; HUVS with emphysema responds well |
| Mycophenolate mofetil (MMF) | Steroid-sparing option |
| Rituximab | Refractory cases |
| Canakinumab (IL-1 inhibitor) | Has shown efficacy in UV specifically |
| Cyclophosphamide-dexamethasone pulse | Reported in severe/refractory cases |
| Omalizumab | Used in a few cases; mixed results |
| Plasmapheresis + IVIG | Rare severe cases, especially with lymphoma-associated UV |
Per Goldman-Cecil Medicine: "Other cases, especially hypocomplementemic urticarial vasculitis, may cause life-threatening involvement of the lungs or other organs and require periods of intensive immunosuppression... treatment decisions must be individualized."
Key Comparison Summary
| Feature | Ordinary Urticaria | Urticarial Vasculitis |
|---|---|---|
| Antihistamines | Highly effective | Often insufficient |
| NSAIDs | Usually avoided | Indomethacin is helpful |
| Dapsone | Second-line | Commonly used |
| Steroids | Short rescue courses only | Often needed long-term |
| Biologics | Omalizumab (excellent) | Rituximab, Canakinumab |
| Steroid-sparing agents | Rarely needed | Azathioprine, MMF commonly used |
- Andrews' Diseases of the Skin, p. 965
- Dermatology 2-Volume Set (Bolognese), Table 18.5-18.6
- Goldman-Cecil Medicine, Urticarial Vasculitis chapter
This is a shared conversation. Sign in to Orris to start your own chat.